摘要
目的 观察不同剂量厄贝沙坦对糖尿病心肌病患者心肌纤维化及心功能的影响。方法 选择2020年5月至2021年4月我院内分泌科接诊的50例糖尿病心肌病患者作为研究对象,按照掷硬币分组法将其分为对照组(25例,0.15 g/d厄贝沙坦片)和试验组(25例,0.30 g/d厄贝沙坦片)。比较两组的血压[舒张压(DBP)、收缩压(SBP)]、血脂[甘油三酯(TG)、总胆固醇(TC)]及血肌酐、心肌纤维化指标[赖氨酰氧化酶(LOX)、基质金属蛋白酶-2(MMP-2)]、心功能指标[左室舒张末期内径(LVEDd)、左室收缩末期内径(LVEDs)、左室射血分数(LVEF)、氨基末端脑钠肽前体(NTproBNP)、6 min步行距离(6MWD)]、炎性因子[白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)]水平、白细胞计数(WBC)、淋巴细胞比率(LYR)。结果 治疗后,两组的DBP、SBP、TG、TC水平低于治疗前,血肌酐水平高于治疗前(P<0.05),但两组间比较,差异无统计学意义(P>0.05)。治疗后,两组的LOX、MMP-2、IL-6、IL-8、TNF-α水平低于治疗前,且试验组低于对照组(P<0.05)。治疗后,两组的LVEDd、LVEDs均小于治疗前,LVEF、6MWD均大于治疗前,NT-proBNP水平均低于治疗前,且试验组优于对照组(P<0.05)。治疗后,两组的WBC均少于治疗前,LYR均高于治疗前,且试验组优于对照组(P<0.05)。结论 与低剂量厄贝沙坦比较,高剂量厄贝沙坦治疗糖尿病心肌病更有利于促进患者心肌纤维化及心功能改善。
Objective To observe the effects of different doses of irbesartan on myocardial fibrosis and cardiac function in patients with diabetes cardiomyopathy.Methods A total of 50 patients with diabetes cardiomyopathy admitted in the endocrinology department of our hospital from May 2020 to April 2021 were selected as the research objects.The patients were divided into control group(25 cases,0.15 g/d irbesartan tablets)and experimental group(25 cases,0.30 g/d irbesartan tablets)according to the coin toss grouping method.Blood pressure[diastolic blood pressure(DBP),systolic blood pressure(SBP)],blood lipids[triglycerides(TG),total cholesterol(TC)]and serum creatinine,myocardial fibrosis indexes[lysyl oxidase(LOX),matrix metalloproteinase-2(MMP-2)],cardiac function indexes[left ventricular end-diastolic diameter(LVEDd),left ventricular end systolic diameter(LVEDs),left ventricular ejection fraction(LVEF),N-terminal pro-brain natriuretic peptide(NT-proBNP),6-min walking distance(6MWD)],inflammatory factors[interleukin-6(IL-6),interleukin-8(IL-8),tumor necrosis factor-α(TNF-α)]levels,white blood cell count(WBC),lymphocyte ratio(LYR)were compared between the two groups.Results After treatment,the DBP,SBP,TG and TC levels in the two groups were lower than those before treatment,and the level of serum creatinine was higher than that before treatment(P<0.05),but there were no significant differences between the two groups(P>0.05).After treatment,the levels of LOX,MMP-2,IL-6,IL-8 and TNF-αin the two groups were lower than those before treatment,and those in the experimental group were lower than the control group(P<0.05).After treatment,the LVEDd,LVEDs in the two groups were smaller than those before treatment,the LVEF and 6MWD were greater than those before treatment,and NT-proBNP level was lower than that before treatment,and those in the experimental group were better than the control group(P<0.05).After treatment,WBC in the two groups was less than that before treatment,LYR was higher than that before treatment,and those in the experimental group were better than the control group(P<0.05).Conclusion Compared with low-dose irbesartan,high-dose irbesartan in the treatment of diabetes cardiomyopathy is more conducive to promote the improvement of myocardial fibrosis and cardiac function.
作者
王杨
付姗姗
WANG Yang;FU Shanshan(Xi'an Gaoxin Hospital,Xi'an 710000,China)
出处
《临床医学研究与实践》
2022年第25期52-55,共4页
Clinical Research and Practice
关键词
不同剂量
厄贝沙坦
糖尿病心肌病
心肌纤维化
心功能
different doses
irbesartan
diabetes cardiomyopathy
myocardial fibrosis
cardiac function
作者简介
王杨(1988-),女,主治医师,学士。研究方向:糖尿病心肌病相关研究。;通讯作者:付姗姗,E-mail:napolss@163.com。
